Although HER2 positivity indicates worse prognosis for breast cancer [1–3], the results of this meta-analysis indicated that further discriminating differences in HER2 amplification magnitude have insignificant prognostic value in adjuvant setting. Here, ERBB2 is linked to breast cancer.